Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2005

View Archived Issues

Rats receiving CRF1 antagonist show reduction in submissive behavior

Ligand updates status of inhouse and partnered programs

Efficacy of LJ-529 in ER-negative breast cancer models

SPC-2968, an HIF-1 inhibitor, in preparation for initial clinical studies in 2006

Preclinical efficacy reported for GI-5005, a therapeutic vaccine for chronic hepatitis C infection

Enzon Pharmaceuticals and Micromet end research collaboration

European Commission approval for Teva's acquisition of Ivax

PharmaGap and OHSU Cancer Institute to collaborate on PKC inhibitors

GSK and Institut Pasteur collaborate to develop AIDS vaccine

American Pharmaceutical Partners to merge with American Bioscience

BioCryst submits IND for injectable formulations of peramivir

Enrollment completed in phase III study of Entereg in postoperative ileus

Phase III trials begin for PF-3512676 for NSCLC

Leo Pharma and Foamix to develop medicated foams for psoriasis

Agile completes phase II study for low estrogen contraceptive patch

Quadramet studied in combination with bortezomib for multiple myeloma

Neuren signs memorandum of understanding for Glypromate phase III trial

GW-610: new anticancer agent with potent and selective profile

New class of selective, orally active MEK1/2 inhibitors for cancer therapy

Feasibility of Syk kinase inhibition with R-406 demonstrated

Studies suggest benefit of IL-1 TRAP in atherosclerosis, CIAS1-associated syndromes

Ambrisentan beneficial in patients with connective tissue diseases and PAH

Obese, dyslipidemic subjects lose weight on rimonabant

Solvay suspends regulatory activities for cilansetron in U.S.

New antihepatitis C agents described in recent GSK patent

Novel agents for diabetes and related complications reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...